How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

19,334 results for

Gold Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients LABORATORY MEDICINE PRACTICE GUIDELINES EDITED BY LORALIE J. LANGMAN AND PAUL J. JANNETTO Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Co-Sponsored byLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Loralie J. Langman Committee Chair Department of Laboratory Medicine and Pathology Mayo Clinic (...) References 101 Table of ContentsLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients 5 Executive Summary Introduction The American Association for Clinical Chemistry (AACC) Acad- emy, formerly the National Academy of Clinical Biochemistry (NACB), has developed a laboratory medicine practice guidelines (LMPG) for using laboratory tests to monitor drug therapy in pain management patients. The scope and purpose of this guideline

2018 American Academy of Pain Medicine

2. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

3. CRACKCast E179 – Drug Therapy in Pregnancy

are some “D” drugs Amiodarone All NSAIDS in the 3rd trimester Carbamazepine Paroxetine Sulfonamides Tetracyclines [3] List 5 dangerous medicines to be avoided if breastfeeding Concerns exist for: Amiodarone Chemotherapeutic/antineoplastic agents Chloramphenicol Ergotamine Gold salts Phenindione Radioactive pharmaceuticals Retinoids Tetracyclines (chronic > 3 weeks) Certain psychotropic medications Codeine Pseudoephedrine Copied from: For more resources on this, see: [4] List 4 dangerous antibiotics (...) CRACKCast E179 – Drug Therapy in Pregnancy CRACKCast E179 - Drug Therapy in Pregnancy - CanadiEM CRACKCast E179 – Drug Therapy in Pregnancy In , by Chris Lipp May 21, 2018 This episode of CRACKCast covers Rosen’s Chapter 179, Drug Therapy in Pregnancy. There is a lot of fear and anxiety often present within pharmacologic therapy in pregnancy, but having informed, shared decision making with patients can lead to safer outcomes and adherence when treating. Check out FOAMCast Shownotes – Key

2018 CandiEM

4. Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment

Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment CBT and treatment resistant schizophrenia Discover Portal Discover Portal Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment Published on 20 November 2018 doi: Cognitive behavioural therapy (CBT) does not improve residual symptoms for people taking clozapine for schizophrenia. Clozapine is the gold (...) augmentation strategies is scarce. We aimed to determine whether cognitive behavioural therapy (CBT) is an effective treatment for clozapine-resistant schizophrenia. Methods We did a pragmatic, parallel group, assessor-blinded, randomised controlled trial in community-based and inpatient mental health services in five sites in the UK. Patients with schizophrenia who were unable to tolerate clozapine, or whose symptoms did not respond to the drug, were randomly assigned 1:1 by use of randomised-permuted

2019 NIHR Dissemination Centre

5. Iron–gold alloy nanoparticles serve as a cornerstone in hyperthermia-mediated controlled drug release for cancer therapy Full Text available with Trip Pro

Iron–gold alloy nanoparticles serve as a cornerstone in hyperthermia-mediated controlled drug release for cancer therapy The efficacy of a chemotherapy drug in cancer therapy is highly determined by the ability to control the rate and extent of its release in vivo. However, the lack of techniques to accurately control drug release drastically limits the potency of a chemotherapy drug.Here, we present a novel strategy to precisely monitor drug release under magnetic stimulation. Methotrexate (...) (MTX), an anticancer drug, was covalently functionalized onto iron-gold alloy magnetic nanoparticles (Fe-Au alloy nanoparticles or NFAs) through 2-aminoethanethiol grafting and the ability of this drug-nanoparticle conjugate (NFA-MTX) in limiting HepG2 (liver carcinoma) cell growth was studied. Well-dispersed NFAs were prepared through pyrolysis.Transmission electron microscopy revealed the average nanoparticle size to be 7.22±2.6 nm, while X-ray diffraction showed distinct 2θ peaks for iron

2018 International journal of nanomedicine

6. AlPcS4-PDT for gastric cancer therapy using gold nanorod, cationic liposome, and Pluronic® F127 nanomicellar drug carriers Full Text available with Trip Pro

AlPcS4-PDT for gastric cancer therapy using gold nanorod, cationic liposome, and Pluronic® F127 nanomicellar drug carriers As a promising photodynamic therapy (PDT) agent, Al(III) phthalocyanine chloride tetrasulfonic acid (AlPcS4) provides deep penetration into tissue, high quantum yields, good photostability, and low photobleaching. However, its low delivery efficiency and high binding affinity to serum albumin cause its low penetration into cancer cells, further limiting its PDT effect (...) , reactive oxygen species and singlet oxygen generation, mitochondrial transmembrane potential and ([Ca2+]i) concentration were further measured to evaluate the mechanism of cell death.The series of synthesized AlPcS4 delivery systems with different drug carriers improve the limited PDT effect in varying degrees. In contrast, AlPcS4 complex with gold nanorods has significant anticancer effects because gold nanorods are not only suitable for AlPcS4 delivery, but also exhibit enhanced singlet oxygen

2018 International journal of nanomedicine

7. Tumor-triggered drug release from calcium carbonate-encapsulated gold nanostars for near-infrared photodynamic/photothermal combination antitumor therapy Full Text available with Trip Pro

Tumor-triggered drug release from calcium carbonate-encapsulated gold nanostars for near-infrared photodynamic/photothermal combination antitumor therapy Different stimulus including pH, light and temperature have been used for controlled drug release to prevent drug inactivation and minimize side-effects. Herein a novel nano-platform (GNS@CaCO3/ICG) consisting of calcium carbonate-encapsulated gold nanostars loaded with ICG was established to couple the photothermal properties of gold (...) nanostars (GNSs) and the photodynamic properties of indocyanine green (ICG) in the photodynamic/photothermal combination therapy (PDT/PTT). In this study, the calcium carbonate worked not only a drug keeper to entrap ICG on the surface of GNSs in the form of a stable aggregate which was protected from blood clearance, but also as the a pH-responder to achieve highly effective tumor-triggered drug release locally. The application of GNS@CaCO3/ICG for in vitro and in vivo therapy achieved the combined

2017 Theranostics

8. Temperature-Sensitive Gold Nanoparticle-Coated Pluronic-PLL Nanoparticles for Drug Delivery and Chemo-Photothermal Therapy Full Text available with Trip Pro

Temperature-Sensitive Gold Nanoparticle-Coated Pluronic-PLL Nanoparticles for Drug Delivery and Chemo-Photothermal Therapy Gold nanoparticle-coated Pluronic-b-poly(L-lysine) nanoparticles (Pluronic-PLL@Au NPs) were synthesized via an easy one-step method and employed as carriers for the delivery of paclitaxel (PTX) in chemo-photothermal therapy, in which Pluronic-PLL acts as the reductant for the formation of AuNPs without the need for an additional reducing agent.The deposition of AuNPs (...) excellent biocompatibility. Compared to Taxol, the PTX-loaded Pluronic-PLL@Au NPs exhibited higher cytotoxicity in MDA-MB-231 cells. All of these results and confocal laser scanning microscopy analysis results suggest that Pluronic-PLL@Au NPs greatly enhance the cellular uptake efficiency of the drug.As confirmed by in vitro and in vivo studies, the combination of chemotherapy and photothermal therapy can cause more damage than chemo- or photothermal therapy did alone, demonstrating the synergistic

2017 Theranostics

9. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. Full Text available with Trip Pro

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the "gold" standard therapy, up to 50% of patients relapse, needing radical cystectomy. Hence, alternative therapeutic strategies have been developed. The aim of the study was to evaluate (...) severe adverse systemic event of hypersensitivity to the MMC in 3 patients (11.5%), and local side effects in 6 patients (26.1%).In the field of alternative strategies to radical cystectomy, the EMDA®-MMC could be considered safe and effective in high-risk NMIBC unresponsive to BCG, as a "bladder sparing" therapy in selected patients. Multicenter studies with a larger number of patients and a longer follow-up might confirm our preliminary results.EudraCT2017-002585-43. 17 June 2017 (retrospectively

2018 BMC Cancer

10. HelpDesk: How accurate are point-of-care urine drug screens in patients taking chronic opioid therapy? (Abstract)

HelpDesk: How accurate are point-of-care urine drug screens in patients taking chronic opioid therapy? In adults treated with opioids for chronic pain, point-of-care urine drug screens (immunoassays) for detecting opioids show a false-negative rate of 1.9%, a sensitivity of 92%, and a specificity of 93% compared with the gold-standard liquid chromatography tandem mass spectrometry. Oxycodone has the highest rate of false-negative results at 25%; methadone has the lowest rate at 4% to 6

2018 Journal of Family Practice

11. Nanocarriers Usage for Drug Delivery in Cancer Therapy Full Text available with Trip Pro

Nanocarriers Usage for Drug Delivery in Cancer Therapy Conventional therapeutic agents have displayed significant shortcomings. For this reason, important achievements have effectively made in biotechnology for delivering the therapeutic agents to the site of action, and diminish side effects. Polymeric carriers, micelles, dendrimers, liposomes, solid lipid carriers, gold carriers, viral carriers, nanotubes and magnetic carriers incorporating cytotoxic therapeutics have developed. To improve (...) biological distribution of therapeutic drugs, some modified carriers have designed in optimal size and modified surface area. Delivery of carriers to target cells could be done by passive and active targeting.

2016 Iranian journal of cancer prevention

12. Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries. (Abstract)

infections and traditional medicines may complicate ARV therapy (ART) in LMICs, which usually takes a public health approach in these settings, with fewer alternative regimens available. This review discusses the issues surrounding pharmacokinetic DDI studies and their application to ART in LMICs, with particular reference to first-line ART regimens.Pharmacokinetic studies with clinical endpoints are the gold standard for informing management of DDIs; however, data relevant to LMICs are sparse and of low (...) Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries. Low- and middle-income countries (LMICs) face specific challenges in the treatment of people living with HIV. Drug-drug interactions (DDIs) involving antiretrovirals (ARVs) are prevalent in all settings and have considerable potential to cause clinical harm to patients via toxicity or reduced efficacy of treatment. Differing comorbidities, endemic

2017 Current opinion in HIV and AIDS

13. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai October 2019 EUnetHTA Joint Action 3 WP4 1 EUnetHTA Joint Action 3 WP4 Version 1.0, 22/10/2019 Relative effectiveness assessment of pharmaceutical technologies USTEKINUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE (...) and Pharmaceutical Benefits Agency (TLV). Relative effectiveness assessment of pharmaceutical technologies. Ustekinumab for the treat- ment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. EUnetHTA Project ID: PTJA07. 2019. PTJA07 - Ustekinumab for active ulcerative colitis October 2019 EUnetHTA Joint Action 3

2020 EUnetHTA

14. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. Full Text available with Trip Pro

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. To compare methotrexate based disease modifying antirheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naive to or with an inadequate response to methotrexate.Systematic review and Bayesian random effects network meta-analysis of trials assessing methotrexate (...) hydroxychloroquine, methotrexate plus leflunomide, methotrexate plus intramuscular gold, methotrexate plus most biologics, and methotrexate plus tofacitinib. The probability of response was 61% with triple therapy and ranged widely (27-70%) with other treatments. No treatment was statistically superior to oral methotrexate for inhibiting radiographic progression. Methotrexate plus abatacept had a statistically lower rate of withdrawals due to adverse events than several treatments.Triple therapy (methotrexate

2016 BMJ (Clinical research ed.)

15. Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease Full Text available with Trip Pro

, gold nanoparticles, microspheres, microcapsules, nanobubbles, microbubbles and dendrimers is being investigated for diagnosis and therapy.This review focuses on formulation, development and advantages of nanosized drug delivery systems which can penetrate the central nervous system for the therapy and/or diagnosis of PD, and highlights future nanotechnological approaches.It is esential to deliver a sufficient amount of either therapeutic or radiocontrast agents to the brain in order to provide (...) Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease Although a variety of therapeutic approaches are available for the treatment of Parkinson's disease, challenges limit effective therapy. Among these challenges are delivery of drugs through the blood brain barier to the target brain tissue and the side effects observed during long term administration of antiparkinsonian drugs. The use of drug delivery systems such as liposomes, niosomes, micelles, nanoparticles, nanocapsules

2016 Current neuropharmacology

16. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. (Abstract)

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Methotrexate is considered the preferred disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis, but controversy exists on the additional benefits and harms of combining methotrexate with other DMARDs.To compare methotrexate and methotrexate-based DMARD combinations for rheumatoid (...) (low quality evidence), methotrexate + leflunomide (moderate quality evidence), methotrexate + intramuscular gold (very low quality evidence), methotrexate + most biologics (moderate to high quality evidence), and methotrexate + tofacitinib (high quality evidence). There was a 61% probability of an ACR50 response with triple therapy, compared to a range of 27% to 64% for the combinations of methotrexate + biologic DMARDs that were statistically significantly superior to oral methotrexate

2016 The Cochrane database of systematic reviews

17. The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery Full Text available with Trip Pro

The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery Nanotechnology is a rapidly growing area of research in part due to its integration into many biomedical applications. Within nanotechnology, gold and silver nanostructures are some of the most heavily utilized nanomaterial due to their unique optical, photothermal, and facile surface chemical properties. In this review, common colloid synthesis (...) methods and biofunctionalization strategies of gold and silver nanostructures are highlighted. Their unique properties are also discussed in terms of their use in biodiagnostic, imaging, therapeutic, and drug delivery applications. Furthermore, relevant clinical applications utilizing gold and silver nanostructures are also presented. We also provide a table with reviews covering related topics.

2014 Archives of toxicology

18. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells Full Text available with Trip Pro

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells Peptide-drug-conjugates (PDCs) are being developed as an effective strategy to specifically deliver cytotoxic drugs to cancer cells. However one of the challenges to their successful application is the relatively low stability of peptides in the blood, liver and kidneys. Since AuNPs seem to have a longer plasma half-life than PDCs, one approach to overcoming this problem would (...) be to conjugate the PDCs to gold nanoparticles (AuNPs), as these have demonstrated favorable physico-chemical and safety properties for drug delivery systems. We set out to test whether PEG coated-AuNPs could provide a suitable platform for the non-covalent loading of pre-formed PDCs and whether this modification would affect the bioavailability of the PDCs and their cytotoxicity toward target cancer cells.Peptides specifically internalized by A20 murine lymphoma cells were isolated from a phage library

2018 Journal of nanobiotechnology

19. Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy? Full Text available with Trip Pro

Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy? A new era of metal-based drugs started in the 1960s, heralded by the discovery of potent platinum-based complexes, commencing with cisplatin [(H₃N)₂PtCl₂], which are effective anti-cancer chemotherapeutic drugs. While clinical applications of gold-based drugs largely relate to the treatment of rheumatoid arthritis, attention has turned to the investigation of the efficacy of gold(I) and gold(III) compounds for anti-cancer (...) applications. This review article provides an account of the latest research conducted during the last decade or so on the development of gold compounds and their potential activities against several cancers as well as a summary of possible mechanisms of action/biological targets. The promising activities and increasing knowledge of gold-based drug metabolism ensures that continued efforts will be made to develop gold-based anti-cancer agents.

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

20. Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy

for approximately 3 visits in a 48 week period of time. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 1000 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy. Study Start Date : December 2013 Estimated Primary Completion Date : June 2019 Estimated Study Completion Date : June 2019 Resource links provided by the National Library of Medicine related (...) Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Quantifying Drug

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>